Juliette Lambert

1.4k total citations
26 papers, 578 citations indexed

About

Juliette Lambert is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Juliette Lambert has authored 26 papers receiving a total of 578 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 8 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Juliette Lambert's work include Acute Myeloid Leukemia Research (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Juliette Lambert is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Juliette Lambert collaborates with scholars based in France, United States and Switzerland. Juliette Lambert's co-authors include Claude Preudhomme, Sylvie Castaigné, Hervé Dombret, Christine Terré, Cécile Pautas, Sylvie Chevret, Xavier Thomas, Emmanuel Raffoux, Rebecca Benner and Ollivier Legrand and has published in prestigious journals such as Journal of Clinical Investigation, Blood and International Journal of Molecular Sciences.

In The Last Decade

Juliette Lambert

23 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juliette Lambert France 10 305 186 182 114 113 26 578
Athanasios Galanopoulos Greece 10 211 0.7× 115 0.6× 159 0.9× 28 0.2× 163 1.4× 40 492
Martin Schwonzen Germany 13 142 0.5× 106 0.6× 238 1.3× 81 0.7× 13 0.1× 27 510
Erica Finolezzi Italy 10 106 0.3× 111 0.6× 103 0.6× 33 0.3× 45 0.4× 22 433
Song Jin China 13 348 1.1× 189 1.0× 262 1.4× 22 0.2× 8 0.1× 68 620
Luis Fayad United States 11 123 0.4× 81 0.4× 275 1.5× 27 0.2× 21 0.2× 33 597
Iuliana Vaxman Israel 13 147 0.5× 312 1.7× 150 0.8× 21 0.2× 34 0.3× 57 489
Jörg Faber Germany 11 109 0.4× 144 0.8× 192 1.1× 10 0.1× 19 0.2× 31 466
Andrew L. Himelstein United States 9 83 0.3× 226 1.2× 339 1.9× 96 0.8× 12 0.1× 17 595
Houston Holmes United States 12 202 0.7× 88 0.5× 319 1.8× 27 0.2× 11 0.1× 39 540

Countries citing papers authored by Juliette Lambert

Since Specialization
Citations

This map shows the geographic impact of Juliette Lambert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juliette Lambert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juliette Lambert more than expected).

Fields of papers citing papers by Juliette Lambert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juliette Lambert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juliette Lambert. The network helps show where Juliette Lambert may publish in the future.

Co-authorship network of co-authors of Juliette Lambert

This figure shows the co-authorship network connecting the top 25 collaborators of Juliette Lambert. A scholar is included among the top collaborators of Juliette Lambert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juliette Lambert. Juliette Lambert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Largeaud, Laëtitia, Juliette Lambert, Philippe Rousselot, et al.. (2024). The AXL inhibitor bemcentinib overcomes microenvironment‐mediated resistance to pioglitazone in acute myeloid leukemia. FEBS Journal. 292(1). 115–128. 5 indexed citations
2.
Hirsch, Pierre, Jérôme Lambert, Maxime Bucci, et al.. (2024). Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study. Blood Cancer Journal. 14(1). 97–97. 3 indexed citations
3.
Martin‐Toutain, Isabelle, Juliette Lambert, Fatiha Merabet, et al.. (2024). Acquired hemophilia A and emicizumab for the treatment of bleeding: two case report and a literature review. Annales de biologie clinique. 82(3). 294–307.
4.
Duployez, Nicolas, Juliette Lambert, Maël Heiblig, et al.. (2023). Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML. Blood. 142(Supplement 1). 4322–4322.
5.
Ranchon, Florence, Étienne Chatelut, Juliette Lambert, et al.. (2023). Anticorps monoclonaux conjugués et bispécifiques en cancérologie – compte rendu de la Journée de Saint Louis 2022. Bulletin du Cancer. 110(12). 1343–1351. 4 indexed citations
6.
Lapillonne, Hélène, Meyling Cheok, Claude Preudhomme, et al.. (2022). Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study. Blood Advances. 6(9). 2773–2777. 5 indexed citations
7.
Lambert, Juliette, Joseph Saliba, Carolina Calderón, et al.. (2021). PPARγ agonists promote the resolution of myelofibrosis in preclinical models. Journal of Clinical Investigation. 131(11). 6 indexed citations
8.
Duployez, Nicolas, Matthieu Duchmann, Laëtitia Largeaud, et al.. (2021). Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study. Blood. 138(Supplement 1). 612–612.
9.
10.
Pautas, Cécile, Emmanuel Raffoux, Juliette Lambert, et al.. (2021). Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia. Bone Marrow Transplantation. 56(6). 1474–1477. 13 indexed citations
11.
Nehme, Ali, Frédéric Picou, Meyling Cheok, et al.. (2020). Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. Blood Advances. 4(20). 5322–5335. 10 indexed citations
12.
Lambert, Juliette, Cécile Pautas, Christine Terré, et al.. (2018). Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 104(1). 113–119. 237 indexed citations
13.
Lambert, Juliette, et al.. (2018). Antimicrobial electrospun collagen nanofibers loaded with Silver nanoparticles and Vancomycin. Proceedings for Annual Meeting of The Japanese Pharmacological Society. WCP2018(0). PO4–11. 1 indexed citations
14.
Micaëlo, Maïté, et al.. (2016). Erysipelothrix rhusiopathiae bacteremia: a challenging diagnosis!. Annales de biologie clinique. 74(5). 613–615. 1 indexed citations
15.
Jannot, Anne‐Sophie, Sophie Rigaudeau, Juliette Lambert, et al.. (2016). The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients. Infection Control and Hospital Epidemiology. 37(7). 845–851. 2 indexed citations
16.
Rigaudeau, Sophie, N. Baron, Juliette Lambert, et al.. (2016). Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity. European Heart Journal - Cardiovascular Imaging. 18(4). jew223–jew223. 74 indexed citations
17.
Rigaudeau, Sophie, A.-L. Taksin, N. Baron, et al.. (2016). Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity. Annales de Cardiologie et d Angéiologie. 65(5). 380–380. 40 indexed citations
18.
Lambert, Juliette, Jérôme Lambert, Olivier Nibourel, et al.. (2014). MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 5(15). 6280–6288. 59 indexed citations
19.
20.
Erny-Albrecht, Katrina, et al.. (1996). Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis.. PubMed. 13(9). 2015–20. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Athanasios Galanopoulos Breakdown of academic impact, for papers by Martin Schwonzen Breakdown of academic impact, for papers by Erica Finolezzi Breakdown of academic impact, for papers by Song Jin Breakdown of academic impact, for papers by Luis Fayad Breakdown of academic impact, for papers by Iuliana Vaxman Breakdown of academic impact, for papers by Jörg Faber Breakdown of academic impact, for papers by Andrew L. Himelstein Breakdown of academic impact, for papers by Houston Holmes
Rankless by CCL
2026